/PEPG
PEPG Stock - PepGen Inc.
Healthcare|BiotechnologyNASDAQ
$5.42+4.23%
+$0.22 (+4.23%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.44
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+139.9%upside
Target: $13.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PEPG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.37 – $5.47
TARGET (TP)$13.00
STOP LOSS$4.99
RISK/REWARD1:17.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.91
52W High$6.72
52W Low$0.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,505,000 | $-1,184,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-97,739,000 | $-84,766,000 | $-68,301,000 | $-27,109,000 | $-1,877,000 |
| Net Income | $-89,981,000 | $-78,626,000 | $-69,104,000 | $-27,281,000 | $-1,889,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.85 | $-3.30 | $-4.42 | $-1.22 | $-0.53 |
Company Overview
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
75%
Hold / Neutral
1
13%
Sell / Underperform
1
13%
Analyst Consensus🟢 Bullish
6 Bullish2 Neutral/Bearish
Price Targets
$18
Average Target
↑ 232.1% Upside
Now
$3
Low
$18
Average
$40
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 9th 2025 | Guggenheim | Initiation | Buy | $6 |
| December 16th 2024 | BofA Securities | Downgrade | Underperform | $3 |
| July 31st 2024 | BofA Securities | Downgrade | Neutral | $12 |
| December 21st 2022 | H.C. Wainwright | Initiation | Buy | $26 |
| May 31st 2022 | Stifel | Initiation | Buy | $24 |
| May 31st 2022 | Wedbush | Initiation | Outperform | $17 |
| May 31st 2022 | SVB Leerink | Initiation | Outperform | $40 |
| May 31st 2022 | BofA Securities | Initiation | Buy | $16 |
Earnings History & Surprises
PEPGBeat Rate
60%
Last 15 quarters
Avg Surprise
+0.6%
EPS vs Estimate
Beats / Misses
9/6
Last 12 quarters
Latest EPS
$-0.52
Q4 2025
EPS Surprise History
Q1 24
+18.8%
$-0.82vs$-1.01
Q2 24
+14.9%
$-0.63vs$-0.74
Q3 24
-20.8%
$-0.87vs$-0.72
Q4 24
+24.1%
$-0.66vs$-0.87
Q1 25
+16.0%
$-0.68vs$-0.81
Q2 25
-27.8%
$-0.92vs$-0.72
Q3 25
+17.6%
$-0.70vs$-0.85
Q4 25
+17.5%
$-0.52vs$-0.63
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.63 | $-0.52 | +17.5% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.85 | $-0.70 | +17.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.72 | $-0.92 | -27.8% | ✗ MISS |
Q1 2025 | Feb 24, 2025 | $-0.81 | $-0.68 | +16.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.87 | $-0.66 | +24.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.72 | $-0.87 | -20.8% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.74 | $-0.63 | +14.9% | ✓ BEAT |
Q1 2024 | Mar 6, 2024 | $-1.01 | $-0.82 | +18.8% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.88 | $-0.98 | -11.4% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.81 | $-0.82 | -1.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.79 | $-0.69 | +12.7% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.87 | $-0.96 | -10.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1.00 | $-0.79 | +21.0% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-0.76 | $-1.23 | -61.8% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.89 | $-0.89 | +0.3% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-7.75 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-1.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.70 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on PepGen, Raises Price Target to $20
📈 PositiveBenzinga•Nov 13, 2025, 05:42 PM
PepGen Q3 EPS $(0.52) Beats $(0.59) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:12 PM
PepGen Issued U.S. Patent For Proprietary PGN-EDODM1 Molecule
📈 PositiveBenzinga•Nov 12, 2025, 12:05 PM
HC Wainwright & Co. Maintains Buy on PepGen, Raises Price Target to $18
📈 PositiveBenzinga•Oct 28, 2025, 12:07 PM
Dyne, PepGen jump as potential beneficiaries of Novartis/Avidity deal
📈 PositiveSeeking Alpha•Oct 27, 2025, 04:09 PM
Wedbush Maintains Outperform on PepGen, Lowers Price Target to $8
➖ NeutralBenzinga•Sep 30, 2025, 12:45 PM
Stifel Maintains Buy on PepGen, Raises Price Target to $12
📈 PositiveBenzinga•Sep 25, 2025, 06:22 PM•Also:
Wedbush Maintains Outperform on PepGen, Raises Price Target to $9
📈 PositiveBenzinga•Sep 25, 2025, 01:33 PM
PepGen shares are trading higher. The company announced the pricing of its $100 million public offering of 31,250,000 shares at $3.20 per share.
📈 PositiveBenzinga•Sep 25, 2025, 01:23 PM
HC Wainwright & Co. Maintains Buy on PepGen, Raises Price Target to $12
📈 PositiveBenzinga•Sep 25, 2025, 11:45 AM
Reported Earlier, PepGen Prices $100M Public Offering Of 31,250,000 Shares Of Common Stock At $3.20 Per Share
➖ NeutralBenzinga•Sep 25, 2025, 06:30 AM
PepGen launches public offering to fund clinical trials; shares up 34%
📈 PositiveSeeking Alpha•Sep 24, 2025, 08:36 PM
PepGen Launches Underwritten Public Offering Of Common Stock; No Terms Disclosed
➖ NeutralBenzinga•Sep 24, 2025, 08:23 PM
PepGen shares are trading higher after the company announced clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose study in patients with myotonic dystrophy type 1.
📈 PositiveBenzinga•Sep 24, 2025, 08:20 PM
PepGen Reports 53.7% Mean Splicing Correction Observed Following A Single 15 mg/kg Dose Of PGN-EDODM1, With All Patients Showing An Improvement In Splicing; PGN-EDODM1 Was Generally Well-Tolerated, With Drug-Related Adverse Events Mild Or Moderate In Severity
📈 PositiveBenzinga•Sep 24, 2025, 08:18 PM
PepGen shares are trading higher. Guggenheim reiterated their Buy rating on the stock and maintained its $6 price target.
📈 PositiveBenzinga•Sep 24, 2025, 05:47 PM
Guggenheim Reiterates Buy on PepGen, Maintains $6 Price Target
📈 PositiveBenzinga•Sep 24, 2025, 01:17 PM
Guggenheim Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $6
📈 PositiveBenzinga•Sep 9, 2025, 12:58 PM
Frequently Asked Questions about PEPG
What is PEPG's current stock price?
PepGen Inc. (PEPG) is currently trading at $5.42 per share. The stock has moved +4.23% today.
What is the analyst price target for PEPG?
The average analyst price target for PEPG is $13.00, based on 1 analyst.
What sector is PepGen Inc. in?
PepGen Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PEPG's market cap?
PepGen Inc. has a market capitalization of $0.37 billion, making it a small-cap company.
Does PEPG pay dividends?
No, PepGen Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
CYBN
Cybin Inc.
$7.18
Mkt Cap: $0.4B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
Explore stocks similar to PEPG for comparison